more

Masimo (MASI)

(Delayed Data from NSDQ)

$139.94 USD

+4.27 (3.15%)

Updated Oct 8, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

Top 37% (94 out of 252)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aphria (APHA) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research Published on October 14,2020

Aphria's (APHA) fiscal first-quarter results are likely to reflect higher sales from medical and adult-use cannabis products.

Why Masimo (MASI) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research Published on October 13,2020

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

MASIPositive Net Change

What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?

by Zacks Equity Research Published on October 13,2020

Intuitive Surgical's (ISRG) third-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment.

3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic

by Sriparna Ghosal Published on October 09,2020

Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.

medical

Masimo Unveils New Wearable Wireless Continuous Thermometer

by Zacks Equity Research Published on October 08,2020

Masimo's (MASI) wearable wireless continuous thermometer offers consumers hassle-free continuous body temperature measurements, thereby eliminating the need for manual measurements.

Masimo's (MASI) Rad-G Pulse Oximeter Receives FDA Clearance

by Zacks Equity Research Published on October 02,2020

Masimo's (MASI) Rad-G Pulse Oximeter receives FDA clearance, thereby allowing clinicians to access the most accurate and reliable pulse oximetry monitoring technologies.

Masimo's (MASI) O3 Regional Oximetry Attains FDA Approval

by Zacks Equity Research Published on September 01,2020

Masimo's (MASI) O3 Regional Oximetry's FDA clearance can help clinicians offer quick and accurate care

medical

Masimo (MASI) Down 0.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research Published on August 27,2020

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MASIPositive Net Change

Masimo Releases Favorable Study Results on Pulse Oximetry

by Zacks Equity Research Published on August 21,2020

The pulse oximetry study result should be a major breakthrough for Masimo (MASI) to capture the neonatal patient care market.

medical

Masimo PVi Gets FDA Approval to Measure Fluid Responsiveness

by Zacks Equity Research Published on August 17,2020

The FDA approval of Masimo's (MASI) PVi system will enable patient safety.

medical

Masimo (MASI) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research Published on July 29,2020

Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q2.

medical

Masimo (MASI) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research Published on July 28,2020

Masimo (MASI) delivered earnings and revenue surprises of 8.97% and 4.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

MASIPositive Net Change

Masimo (MASI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research Published on July 21,2020

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MASIPositive Net Change

Masimo (MASI) Introduces Automation and Connectivity Solution

by Zacks Equity Research Published on July 15,2020

Masimo's (MASI) UniView: 60 leverages the Masimo Hospital Automation platform to boost clinical workflows.

medical

4 Telehealth Stocks to Gain on Virtual Response to Coronavirus

by Sreoshi Bera Published on July 13,2020

Advancement in technology has helped cater to the growing medical demand during the coronavirus pandemic. Here are four telehealth stocks set to boom.